Prophylactic dapagliflozin attenuates pulmonary vascular remodelling, preserves right ventricular function, and maintains exercise capacity in a monocrotaline-induced pulmonary hypertension rat model

29 August 2026 (11:15 - 12:00)

Organised by:

Video

Abstract

Slides

About the speakers

Doctor Suha Asal

Ministry of Health Corlu State Hospital, Istanbul (Turkiye)

Doctor Ahmet Oz

Istanbul Education and Research Hospital, Istanbul (Turkiye)

7 More presentations in this session

Plasma apelin levels in pulmonary arterial hypertension: a potential early diagnostic biomarker?

Doctor C. Tunca (Ankara, TR)

Abstract Slides Video

Exploratory study on the inhibitory effect of dihydrotanshinone on RNA-binding protein (HuR) in the treatment of pulmonary heart disease with right ventricular fibrosis

Professor X. Yu (Guangzhou, CN)

Abstract Slides Video

Multi-omics interrogation of energy metabolism reveals novel causal targets in pulmonary arterial hypertension

Mr S. Hou (Shanghai, CN)

Abstract Slides Video

Cardiovascular and metabolic comorbidities shape endothelial dysfunction in pulmonary arterial hypertension and may influence treatment: insights from a multicenter translational network

Associate Professor R. Madonna (Pisa, IT)

Abstract Slides Video

CCR6⁺ T cells as potential drivers of inflammation in chronic thromboembolic pulmonary hypertension

Miss C. Ferreira (Coimbra, PT)

Abstract Slides Video

Access the full session

Pulmonary hypertension: pathophysiology and mechanisms

The Event

ESC Congress 2026

29 August 2026 11:15 CET

You may be interested in

Congress Presentation

Empagliflozin halts deleterious right ventricular remodeling in a model of rats with right ventricular dysfunction

29 August 2025

Congress Presentation

EPA:DHA 6:1 prevents right ventricular dysfunction and lung vascular remodeling in monocrotaline-induced pulmonary arterial hypertension in rats by mitigating inflammatory and pro-oxidant responses

18 May 2025

Congress Presentation

Treatment with Ralinepag Improves Outcomes in Patients with Connective Tissue Disease Associated with Pulmonary Arterial Hypertension: Results from the Phase 3 ADVANCE Outcomes Study

29 August 2026

Congress Presentation

Immune–metabolic crosstalk between T cells and interstitial macrophages drives pulmonary vascular remodeling in cardiometabolic HFpEF

28 August 2026

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

ESC 365 is supported by

Explore sponsored resources